




# 15TH ANNUAL HEALTHCARE INVESTOR CONFERENCE

.....

11th October 2023



# MEET THE OPTIMUM TEAM



Mary  
Clark



Nick  
Bastin



Hollie  
Vile



Jonathan  
Murphy



Eva  
Haas



Stephen  
Adams



Hana  
Malik



Jonathan  
Edwards



Richard  
Staines



Charlotte  
Hepburne-Scott




Zoe  
Bolt



Vici  
Rabbetts



Eleanor  
Cooper



Elena  
Bates



Katie  
Flint



Vareen  
Outhonesack



Monica  
Clark



Abbie  
Murphy



Ellie  
Reston



Mochi

## **INTERNATIONAL STRATEGIC COMMUNICATIONS FOR LIFE SCIENCES, HEALTHCARE & INDUSTRIAL BIOTECHNOLOGY**

We are specialists with an in-depth understanding of how to communicate complex scientific information using a multi-channel approach to help you through various growth stages. We have been trusted by hundreds of clients, both public and private, large and small, to help them on their journey.



Strategic, proactive & effective corporate communications and investor relations in Europe and US - helping clients communicate a compelling story to important stakeholders



Healthcare, life sciences & industrial biotech specialists who have worked with over 300 companies



Successful track record helping companies raise their profile in the international top tier media ahead of fund raisings



Unrivalled network of contacts in the investment community and media, across Europe and US



In-depth research and analysis, combined with knowledge of the global healthcare industry, enabling us to provide clients with the best-informed and most creative advice on building a compelling investment story



Team of experienced, senior specialist healthcare advisors

## SPEAKERS



**BIOCENTURY**



**iCG**

**Jefferies**

**novo  
holdings**



**Sofinnova  
partners**

## Networking drinks reception hosted by Cooley & ICG

Please join us from 5:30pm for bubbles & bites in the  
Williams Lounge, Wellcome Collection.

**Cooley**

**iCG**



# AGENDA

**12:00pm-12:50pm** Registration & networking lunch

**Welcome from Mary Clark, Chief Executive Officer, Optimum Strategic Communications**

**1:00pm-2:00pm** **How can the UK better capitalise on its life sciences prowess?**

Chair: Dan Mahony, UK Government Life Sciences Investment Envoy & Chair of BIA

- Annalisa Jenkins, Non-Executive Director, Genomics England
- Allan Marchington, Managing Director, ICG
- Gil Bar-Nahum, Managing Director, Jefferies International

**2:00pm-2:45pm** **Fireside chat with Clive Cookson & Kasim Kutay**

Chair: Clive Cookson, Senior Science Writer, Financial Times

- Kasim Kutay, Chief Executive Officer, Novo Holdings

**2:45pm-3:30pm** **Tea break & networking**

**Introduction by Eva Haas, Director, Optimum Strategic Communications**

**3:30pm-4:15pm** **Keynote and fireside chat with Professor Sir Chris Whitty & Nick Bastin**

Chair: Nick Bastin, Managing Director, Optimum Strategic Communications

- Professor Chris Whitty, Chief Medical Officer for England, and Expert Adviser, UK Government

**4:15pm-5:15pm** **Navigating turbulent markets**

Chair: Stephen Hansen, Director of BioPharma Intelligence, BioCentury

- Linden Thomson, Fund Manager, AXA Investment Managers
- Geraldine O'Keefe, Partner, EQT Life Sciences
- Naveed Siddiqi, Senior Partner, Novo Holdings
- Joe Anderson, Partner, Sofinnova Partners

**5:15pm-5:25pm** **Optimum's featured charity: Ariana Smiles - a Special Named Fund @CCLG**

Stephanie Seales Gabbitas, Ariana Smiles

Charley Scott, Ariana Smiles

**5:25pm-5:30pm** **Thank you & closing from Optimum**

Mary Clark, Chief Executive Officer, Optimum Strategic Communications

**5:30pm-7:30pm** **Networking reception drinks**

Sponsored by Cooley and ICG

# WELCOME TO OPTIMUM'S 15TH ANNUAL HEALTHCARE INVESTOR CONFERENCE

Celebrating our Crystal Anniversary, the conference is now firmly established as the major healthcare investment thought leadership event in Europe.

More than that, it's a great opportunity for companies and investors to meet and talk in a relaxed setting.

This year, we have a truly illustrious group of speakers who are really going to make things sparkle. I'd like to personally thank them all for taking the time to be here.

We begin with what promises to be a lively debate, titled 'How can the UK better capitalise on its life sciences prowess?', which will examine what we are doing well here in the UK and what could be improved. It will be chaired by the unstoppable.

Next up is a fireside chat between Clive Cookson from the Financial Times and Kasim Kutay, CEO of Novo Holdings. Kasim will discuss the trends driving its investment strategy and its commitment to investing in companies that contribute to improving people's health and the sustainability of society and the planet.

After a tea break we return for the keynote presentation from Professor Chris Whitty, the UK Government's Chief Medical Adviser, who we thank for sharing his valuable time and insights.

Stephen Hansen, Editor of BioCentury, chairs the final panel of the day, 'Navigating turbulent markets', where an expert panel of investors will discuss how companies can best secure the finance they need to drive innovation and develop new therapies.

The last year has been quite a rollercoaster, so this panel will be a fitting - and we hope illuminating - end to the day's formal events.

The reversal we have seen in markets since the pandemic, with incredible exuberance peaking in 2021 and then ebbing away, is a reminder that change is the only constant.

Resilience and determination are needed to stay the course. But M&A, private fund raises and new drug launches continue - and we remain excited by the constant dynamism of the sector.

Communications have a key role to play in amplifying the good news and explaining the bad. Never has the careful explanation of complex situations been more critical to the success of market participants. Companies need to control their own narratives.

As always, we encourage questions and debate during the conference, so please participate in person and join the conversation on social media using today's hashtag **#OptimumConference2023**.

A summary of the sessions will feature on the Insights page of our website and social media channels in the coming weeks.

Our featured charity Ariana Smiles is a Special Named Fund at Children's Cancer and Leukaemia Group, which is raising funds for research into precision oncology medicine for leukaemia. Please take the opportunity to speak with them and learn more about Ariana's story.

We have an exceptional team of people at Optimum, all of whom will be at the conference - so please do introduce yourselves.

I hope you enjoy our conference and join us for the evening drinks reception that follows, very kindly sponsored by Cooley & ICG. It will be a great opportunity to connect with peers and colleagues, old and new.

Best wishes,

*Mary Clark*

Mary Clark, CEO, Optimum Strategic Communications

## SPEAKERS

This year's event once again hosts another stellar line up of industry speakers, as well as the most influential investors in the healthcare sector, who will be sharing their views and providing insights on the rapidly changing industry landscape.



**Mary Clark, Chief Executive Officer, Optimum Strategic Communications**

Mary has a 25-year successful track record in providing strategic corporate and financial communications to both early- and late-stage international biotech, life sciences and healthcare companies. She has worked with over 300 healthcare clients across Europe and the US. She has supported her clients on raising billions in financing, and has developed and executed several high-profile campaigns to strategically position companies ahead of major transactions, IPOs or M&A. She set up Optimum Strategic Communications in 2017 and it is now established as one of the life sciences and healthcare sector's leading strategic communications firms in Europe. The company represents some of the most exciting and innovative biotech companies in the world, as well as the largest VC funds investing in the sector.



**Eva Haas, Director, Optimum Strategic Communications**

Eva has 25 years' experience in fund management and company analysis across the global healthcare sector. She lived in New York for 7 years covering the US. She was recently at Schroder Investment Management where she was responsible for the analysis and valuation of publicly listed & about-to-be-listed healthcare companies in medical devices & supplies, diagnostics, biotechnology, pharma, life sciences tools, healthcare distribution, pharmacy benefit management, hospitals & health insurance. Eva has a PhD in Biochemistry from Bristol University. She is also a fluent German speaker.

## How can the UK better capitalise on its life sciences prowess?


With world-renowned universities pursuing cutting-edge science, a deep pool of talent, and great infrastructure, the UK has long been a hotspot for innovation. But is it truly capitalising on its brainpower? What hurdles does it face? And can it maintain its position as a top-tier life sciences hub amidst growing competition from around the globe? A panel of industry leaders will discuss what needs to be done to ensure the UK fulfils its potential.



### **Chair: Daniel Mahony, UK Government Life Sciences Investment Envoy & Chair of BIA**

Dan chairs the board of the BioIndustry Association (BIA), the industry trade association for UK life sciences, and holds non-executive directorships at the Wellcome Sanger Institute (a world leading genomics research centre), Sernova (a Canadian TSX-listed cell therapy company) and Keepabl (a UK based, privately-owned provider of SaaS solutions for GDPR compliance). In 2022, he was appointed as the Life Sciences Investment Envoy by the UK Government.

Dan is currently Chairman of Trellus Health plc, an LSE-listed digital health company. He was previously Entrepreneur-in-Residence at Evotec (UK) Limited where he was responsible for the EVOequity investment portfolio. Prior to joining Evotec, he was Co-Head of Healthcare at Polar Capital where he launched the healthcare business in 2007 growing it to over \$4 billion of assets under management. Dan was formerly head of European healthcare research at Morgan Stanley, an analyst at ING Barings Furman Selz in New York and a postdoctoral scientist at DNAX Research Institute in Palo Alto. He has over 25 years of experience within global healthcare covering biotechnology, medical technology and healthcare services.



### **Annalisa Jenkins, Non-Executive Director, Genomics England**

Dr Annalisa Jenkins, M.B.B.S., F.R.C.P. is a life sciences thought leader with over 25 years of experience building and financing companies pursuing cures for the most challenging diseases globally. She has consistently mentored leadership teams advancing programmes from basic research through clinical development, regulatory approval, and into healthcare systems globally. Dr Jenkins graduated in Medicine at the University of London and received her Fellowship of the Royal College of Physicians London. She trained in Cardiovascular medicine and was a research fellow at Imperial College.

Earlier in her career, Dr Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of Surgeon Lieutenant Commander. She also held senior leadership roles at Merck Serono and Bristol Myers-Squibb over 15 years.


Dr Jenkins served as President and CEO of Dimension Therapeutics, a leading gene therapy company she took public on NASDAQ and subsequently sold to Ultragenyx. Following her relocation back to the UK, she developed a portfolio of roles

spanning the public, private and charitable sectors including Genomics England, The King's Fund, British Heart Foundation and Chair of YouBelong, a leading mental health care charity. She is also a Board member of several growing public and private companies including Oncimmune, AVROBIO, COMPASS Pathways, Affimed and Mereo Biopharma. Dr. Jenkins serves on a number of advisory boards and contributes publicly on leadership with purpose, social entrepreneurship, diversity and innovation.



**Allan Marchington, Managing Director and Head of Life Sciences, ICG**

Allan joined ICG in January 2021 and is Managing Director and Head of Life Sciences, responsible for the Life Science Fund strategy and team at ICG. Prior to ICG, Allan was Founder and Managing Partner of Bridge Valley Ventures, a successful life sciences investor, having been a Partner and Founder of Apposite Capital and before this at Abingworth. Formerly a PhD medicinal chemist at Pfizer, he later founded and was CEO of his own life sciences company before it was successfully acquired by Millennium Pharmaceuticals Inc. in 2000 where he became SVP Technology. On his return to the UK in 2003 Allan joined Abingworth to begin his investment career.



**Gil Bar-Nahum, Managing Director and EMEA Head of Biotechnology, Jefferies International**

Gil is a Managing Director and EMEA Head of Biotechnology in the Global Healthcare Investment Banking Group at Jefferies and is based in London. He leads the team with a primary focus on innovative companies in Europe and Israel. Gil has over 20 years of investment banking experience and has executed transactions for biotechnology, pharmaceutical, medical technology, and life science tools companies. In the last several years, Gil has led the execution of more than 60 financings, including 30+ IPOs for foreign private issuers (on NASDAQ), raising more than US\$5bn. Since joining Jefferies in 2009, Gil has also advised on more than a dozen cross-border M&A transactions. From 2002-2009 Gil was part of UBS Investment Bank's Global Healthcare Group, based primarily in the US. Prior to that, Gil worked as an Equity Research Analyst for UBS where he served as an Associate Director covering companies in the Life Science Tools and Biotechnology space.

Gil received his PhD in Basic Medical Sciences from the Department of Biochemistry at the Sackler Institute of New York University School of Medicine. The subject of his doctorate work was published twice in the journal Cell. Gil also received an MSc from New York University's School of Medicine in Cell and Molecular Biology and a BSc from the University of Illinois in Microbiology.



## Fireside chat with Clive Cookson & Kasim Kutay

As CEO of Novo Holdings, responsible for managing the assets and wealth of the Novo Nordisk Foundation, Kasim discusses the trends driving the Company's investment strategy and its commitment to investing in companies that contribute to the sustainability of society and the planet.



### **Chair: Clive Cookson, Senior Science Writer, Financial Times**

Clive Cookson has worked in science journalism for the whole of his professional life. He left Oxford University with a First-Class Honours degree in chemistry and, after training on the Luton Evening Post, joined Times Higher Education - first as science correspondent in London and then as American Editor in Washington.

Clive returned to London as technology correspondent of The Times and then moved to BBC Radio as science and medical correspondent. He went back to print journalism as technology editor of the Financial Times. Since 1991 he has been science editor at the FT, leading a writing team covering science and health, pharmaceuticals and biotechnology. He has won numerous science journalism awards, including British Science Writer of the Year 2022.



### **Kasim Kutay, Chief Executive Officer, Novo Holdings**

Kasim Kutay is Chief Executive Officer of Novo Holdings A/S, Denmark, a position he has held since September 2016. In addition, Kasim is a member of the Board of Directors of Novo Nordisk A/S and Novozymes A/S.

From 2009 to 2016 Kasim was a Partner and member of the Global Management Committee of Moelis & Co. From 1989 to 2007 Kasim held a number of positions at Morgan Stanley, including chair of the European Healthcare Group. Kasim was a member of the Board of Trustees of Northwick Park Institute for Medical Research, UK, from 2005 to 2016. Kasim was a member of the Board of Governors from 2006 to 2011 and the Investment Committee from 2011 to 2016 of the School of Oriental and African Studies (SOAS), UK.

Kasim is a member of the Board of CW+, Chelsea and Westminster Hospital NHS Foundation Trust. He is also a UK national and holds a MSc. and BSc. in Economics from the LSE (London School of Economics and Political Science).

## Keynote and fireside chat with Nick Bastin & Professor Sir Chris Whitty

Professor Whitty, UK Government's Chief Medical Adviser and head of the public health profession, as well as a practising NHS Consultant Physician and epidemiologist will share his insights. He will present a keynote speech, followed by a fireside chat with Optimum's Nick Bastin and a Q&A session.



### **Professor Chris Whitty, Chief Medical Officer and Expert Adviser, UK Government**

Professor Chris Whitty is Chief Medical Officer (CMO) for England, the UK government's Chief Medical Adviser and head of the public health profession. Chris is a practicing NHS Consultant Physician at University College London Hospitals (UCLH) and the Hospital for Tropical Diseases, and a visiting professor at Gresham College, London. Chris is an epidemiologist and has undertaken research and worked as a doctor in the UK, Africa and Asia. He was Professor of Public and International Health at the London School of Hygiene and Tropical Medicine (LSHTM) before becoming CMO and remains an honorary professor.

Chris was the Chief Scientific Adviser for the Department of Health and Social Care (DHSC) from January 2016 to August 2021, with overall responsibility for the department's research and development, including being head of the National Institute for Health Research (NIHR), the government's major funder of clinical, public health, social care and translational research. Chris was the interim Government Chief Scientific Adviser from 2017 to 2018, including during the Novichok poisonings. Before that, he was the Chief Scientific Adviser at the Department for International Development (DFID), which included leading technical work on the West Africa Ebola outbreak and other international emergencies.



### **Chair: Nick Bastin, Managing Director, Optimum Strategic Communications**

Nick has over 28 years of experience advising companies and individuals from over 35 different markets on a wide range of multi-market, multi-stakeholder communications. Nick specialises in helping clients build powerful narratives around corporate reputation, employer brand and investor and capital market objectives. Nick has strong transaction experience and has helped clients raise over €30bn through IPOs and has advised on M&A transactions with a combined deal value in excess of €150bn.

## Navigating turbulent markets

Over the last few years, the pace of world class innovation has quickened, supported by a boom in private investment - yet this has not translated through to public markets. Instead, 2023 has seen weaker global public markets, where life sciences companies have struggled. Our panel of experts discuss what this means for companies looking at how to fund the next stage of their development.



**Chair: Stephen Hansen, Director of BioPharma Intelligence, BioCentury**

Stephen is BioCentury's Director of BioPharma Intelligence in the UK, the company's primary point of contact with European companies and investors.

Stephen has covered clinical development, corporate strategy and finance in Europe, the US and China for BioCentury for over a decade and is a frequent contributor to BioCentury's quarterly Financial Markets Preview and annual Buyside View and European Finance reports. He holds B.A.s in Biology and History from Bethel University and an M.Phil. in History from Oxford University.



**Linden Thomson, Fund Manager, AXA Investment Managers**

Linden leads investment in the AXA IM Framlington Biotech Fund and AXA IM Framlington Healthcare Fund. She has nearly two decades of buy-side and sell-side experience as one of the early specialists in the biotechnology sector. Linden's formative career was spent with Goldman Sachs in the Global Investment Research team covering healthcare/biotechnology. Subsequently she joined a healthcare hedge fund at start-up stage, as a key member of the team that built and launched the fund. She has been at AXA IM Framlington since 2011. She holds a BSc in Biology (Medical Microbiology Hons) from the University of Edinburgh and is a CFA Charterholder.



**Geraldine O'Keeffe, Partner, EQT Life Sciences**

Geraldine O'Keeffe joined EQT in 2008 and is a Partner in the EQT Life Sciences team. Geraldine worked for LSP from 2008 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences.

Prior to joining LSP, Geraldine worked as a Senior Equity Research analyst at Fortis Bank in Amsterdam, The Netherlands. Prior to Fortis, Geraldine was Head of Infectious disease at medical diagnostic company Biotrin (now part of Diasorin) in Dublin, Ireland.

Geraldine holds an BSc Hons in Microbiology and Biochemistry, University College Cork, an MSc in Biotechnology from University College Galway, and a Graduate Diploma in Business Studies from Dublin School of Business.



### **Naveed Siddiqi, Senior Partner, Novo Holdings**

Naveed joined Novo Holdings A/S in 2019 and works from London and Copenhagen as a Senior Partner in Venture Investments.

He brings more than 25 years of experience in life science venture investments and investment banking. Between 2013 and 2018, he was Partner at Andera Partners, a Paris based venture capital and growth equity firm with over 2 billion euros under management, focusing on life science investing. He has also worked for Nomura Phase4 Ventures, Nomura International, EFG Corporate Finance, KPMG and as a medical doctor in the UK's National Health Service. During his career he has served on multiple European and US boards including at Novo Holdings with the Boards of Reviral (acquired by Pfizer), Vectivbio (IPO on NASDAQ), F2G Ltd, Amolyt SAS and Alentis Therapeutics. He is a Board Observer for Numab AG.

Naveed obtained his medical degree from Guy's and St Thomas's Hospital Medical School (now King's College London). Later, he also qualified as a chartered accountant from the Institute of Chartered Accountants England & Wales.



### **Joe Anderson, Partner, Sofinnova Partners**

Joe is a Partner at Sofinnova Partners, focusing on growth stage life science companies. He joined Sofinnova in 2020 from Arix Bioscience plc, an LSE-listed venture capital firm where he was co-founder and CEO for 5 years.

Joe has extensive experience in the healthcare and life science industries, including 12 years as partner at Abingworth LLP, where he led venture-style investments in public companies and the formation of the firm's public equities fund.

As an investor and active board member he has helped companies with financings, IPOs, and M&As, including Algeta (sold to Bayer for \$2.9bn), Amarin (listed on the Nasdaq), Autolus (listed on the Nasdaq) and Cytos (merged with Kuros).

His early career was at the Wellcome Trust where he became head of the strategy group for 9 years. He then moved into equities research as a pharmaceuticals analyst at Dresdner Kleinwort Benson, and then fund management with the global healthcare & biotechnology fund at First State Investments, before moving into venture capital in 2004.

Joe holds a Ph.D. in Biochemistry.

# FEATURED CHARITY



## Ariana Smiles

**Ariana Smiles is a Special Named Fund at CCLG raising funds for research into precision oncology medicine for leukemia.**

We are pleased to have Stephanie & Charley join us today at the conference to highlight the great work of the team behind the Ariana Smiles Fund.



### Stephanie Seales Gabbitas

Stephanie and her husband Chris set up Ariana Smiles following their daughter Ariana's diagnosis with Acute Lymphoblastic Leukaemia in November 2020, with the aim of increasing awareness of current paediatric cancer protocols, and encouraging research into kinder treatments and increased funding. Ariana successfully reached the end of her treatment in March 2023. Originally an actress by profession, Stephanie now runs the largest group of early years ballet classes in South East England through the Babyballet network, and divides her time between managing her business and fundraising for Ariana Smiles.



### Charley Scott

Charley was for many years a prime time TV director across many platforms and channels, and now runs her own company, [shortfilms.london](https://www.shortfilms.london/), which showcases the skills of London's finest film and television professionals. Charley's daughter Jess was diagnosed with T-Cell Non-Hodgkin Lymphoma at the age of 2; her treatment was successful and she is thriving. Charley is a great supporter of Ariana Smiles and has campaigned tirelessly to increase and improve oncology funding, awareness and resources for families, recently releasing The Oncology Guide, a ground-breaking information app for newly-diagnosed children and their loved ones.

Ariana was five years old when in November 2020 she was diagnosed with acute lymphoblastic leukaemia (ALL), a cancer of the blood.



To read more about Ariana's inspiring story or to support the amazing work Ariana Smiles does, please visit:

<https://specialnamedfunds.cclg.org.uk/ariana-smiles/>



# AWARDS 2023

Optimum clients celebrated in the 2023 in various high profile life science awards, tonnes of nominations and winners, and the year isn't over yet!



# OPTIMUM'S CLIENT NEWS

## Financings

 <p>Oversubscribed €45m Series B Financing</p>	 <p>Extension of Series A Financing to €82m</p>	 <p>Innovate UK Financing to Develop Potential Disease Modifying Therapeutic for Huntington's Disease</p>	 <p>Novo Holdings Invests in \$105m Series C Funding of Alentis Therapeutics</p>
 <p>\$30m Investment from Medicxi</p>	 <p>€47.75m Series A Financing Extension</p>	 <p>€16.5m Seed Financing</p>	 <p>\$61m Series A Financing</p>
 <p>Over \$413m Raised by BII Portfolio Companies to Date</p>	 <p>Biocomposites Invests in Renovos Biologic</p>	 <p>Seed Financing to Develop Novel Oral Therapies for Ophthalmologic Diseases</p>	 <p>€12m Series A Financing</p>
 <p>Novo Holdings Invests in Hemab \$135m Financing</p>	 <p>€6m Seed Financing</p>	 <p>\$75m Private Placement Financing</p>	 <p>€17.5m Financing</p>
 <p>€72m Financing</p>	 <p>£27m Series B Financing</p>	 <p>Participates in \$290m Strategic Financing of Sangon Biotech</p>	 <p>\$200m Investment for Developing First Fully Functional Quantum Computer</p>



\$68m Series A  
Financing



Undisclosed Seed  
Financing



\$30m Series B  
Financing



€28m Series A  
Financing



€134.2m Investment  
in Fundamental  
Cardiometabolic  
Research



Announces \$400m  
Medicxi IV



Sofinnova Partners  
and Apollo Enter \$1B  
Strategic  
Collaboration



First Close of Fourth  
Fund Raising €95m

## Clinical milestones



Positive Data from  
RESMAIN Study for  
Treatment of CTCL



Positive Phase 2  
Data from Atrial  
Fibrillation  
Clinical Trial



Successful Phase 3  
NeflgARD Trial  
Evaluating Nefecon®  
in IgAN



FDA Approval of  
MED3000 and UK  
Launch of Eroxon®



Partner Verrica  
Reports Successful  
Interim Phase II  
Data with LTX-315



Positive Additional  
Data from Pivotal  
Alphapump® Study  
(POSEIDON)



Positive Phase 3  
ENHANCE Studies  
in COPD



Phase 2a AIR Trial  
Data Showed  
Sustained Disease  
Stabilisation and  
Increased Lung  
Function in IPF Patients

## BioIndustrials



€54m Series C  
Financing Extension



€8m Series A Paving  
the Way for  
Commercial-Scale  
Production Facility























Novo Holdings Invests  
€86m in 21st.BIO, a  
New Bioindustrial  
Scale-up



€84.7m Funding to  
Establish the World's  
First Interdisciplinary  
Research Center for  
Carbon Capture

# M&A & Deals

 <p>Agreement with Duality Biologics</p>	 <p>Expands Pipeline with Acquisition of Theragnostics Ltd</p>	 <p>BioInnovation Institute Welcomes Eight New Companies to its Venture Lab Program</p>	 <p>Adds Proprietary NanoBone® Technology to its Portfolio Through the Acquisition of Artoss GmbH</p>
 <p>\$1.7bn Collaboration with Merck &amp; Co.</p>	 <p>Agreement with Sebela Pharmaceuticals for NTCD-M3</p>	 <p>\$480m Strategic Collaboration with Shionogi</p>	 <p>Agreement with Haleon to Commercialise MED3000 in the USA</p>
 <p>Agreement with Great Ormond Street Hospital at New Gene Therapy Manufacturing Centre</p>	 <p>Medicxi Portfolio Company MiroBio Acquired by Gilead for \$405m</p>	 <p>Acquisition of Two Product Portfolios from Sanofi</p>	 <p>TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI®</p>
 <p>Acquisition of Paratek Pharmaceuticals</p>	 <p>License Agreement with Biocytogen Pharmaceuticals</p>	 <p>Licences Innovative Oral Delivery Technology for Metabolic Syndrome Related Diseases</p>	 <p>Novo Holdings Portfolio Company Reviral Acquired by Pfizer for \$525m</p>
 <p>Novo Holdings Portfolio Company Syndesi Acquired by Abbvie for \$1bn</p>	 <p>Acquired by Lonza</p>	 <p>Medicxi Portfolio Company Versanis Bio Acquired by Lilly for \$1.9bn</p>	 <p>Medicxi-seeded Villarlis Therapeutics Acquired by Incyte for up to \$1.4bn</p>

## INTERNATIONAL STRATEGIC COMMUNICATIONS USING A OUR MULTI-CHANNEL APPROACH

- ✓ Access to investors
- ✓ Sellside analyst relations
- ✓ Media relations
- ✓ Profile raising
- ✓ Corporate communications
- ✓ Conference support
- ✓ Crisis communications
- ✓ Content development
- ✓ Private financing
- ✓ IPOs
- ✓ M&A
- ✓ Perception studies
- ✓ Messaging
- ✓ Narrative development
- ✓ Digital & social media
- ✓ Presentation & media coaching



Podcast featuring key thought leaders of the  
life sciences industry

Amsterdam



London



New York



Stockholm



Zurich





# OPTIMUM INSIGHTS

Our website hosts weekly insights from across the healthcare industry. Top Takeaways from today's conference will be summarized here in the coming weeks...

If you would like to join our mailing list please contact us on [contact@optimumcomms.com](mailto:contact@optimumcomms.com)

**"If I knew then, what I know..."**

Top take-aways from:

- Niell Martin, Artios
- Dan Mahony, BIA
- Eva-Lotta Allon, Draupnir Bio
- Stephanie Lecuzon, Stifel
- Chaired by Mike Ward, Clarivate



**ANGLO NORDIC LIFE SCIENCE CONFERENCE**

Co-chaired by 



artios BIA draupnir bio STIFEL © Clarivate


**Bloomberg's insight on the challenges facing the UK's life sciences sector**




**LSX & Jefferies**

How to prepare for the busiest week in biopharma!



**Top tips for the 'Optimum' Launch of your company**

[Read more](#)



**Is a world without disease possible?**

Thoughts from pharmaphorum's World Without Disease Summit by Stephen Adams



**The AI Summit:**

Top takeaways by Stephen Adams




# OPTIMUM'S WOMEN AND GIRLS IN SCIENCE AWARENESS DAY CAMPAIGN

To celebrate International Awareness Day of Women & Girls in Science, we wanted to share the hugely inspiring anecdotes and viewpoints that demonstrate the collective passion around gender equality and the recognition of the pivotal work Women in Science continue to deliver.

Here is what the 70 amazing women we are lucky to work with had to say:

[Optimum's Women & Girls in Science Campaign 2023](#)




# DID YOU KNOW THAT OPTIMUM HOSTS ITS OWN PODCAST?

Optimum Perspectives features regular episodes highlighting the latest innovation and developments in life sciences, with industry leaders of the healthcare sector and goes out to our vast network of investors, media and industry influencers.



Listen now on all major streaming platforms



Catch up with all episodes on our website and follow the show to listen as they land!

[www.optimumcomms.com/podcast](http://www.optimumcomms.com/podcast)



**Will West**  
Chief Executive Officer  
CellCentric



**Klaas Zuideveld**  
Chief Executive Officer  
Versameb



**Dan Mahony**  
UK Government Life  
Sciences Envoy



**Renée Aguiar-Lucander**  
Chief Executive Officer  
Calliditas Therapeutics



**Søren Møller**  
Head of Novo Holdings  
Seed Investments



**Chris Martin**  
Senior VP of Commercial  
Verona Pharma



**Jeremy Skillington**  
Chief Executive Officer  
Poolbeg Pharma



**Young Kwon**  
Chief Executive Officer  
Alchemab Therapeutics




**Eva Haas**  
Optimum Strategic  
Communications



**Mary Clark**  
Optimum Strategic  
Communications







Please contact us to see how we can help your strategic communications  
[mary@optimumcomms.com](mailto:mary@optimumcomms.com)

